Catalyst Biosciencesnow Known As Gyre Therapeuticswas Founded In 2002 And Focuses On Developing Innovative Therapeutics For Serious Medical Conditionsthe Company Specializes In Protease Engineering To Create Optimized Molecules That Regulate Biological Systemsparticularly In The Areas Of Hematologyfibrotic Diseasesand Complement Mediated Disorders Gyre Therapeutics Is Advancing Several Key Productsincluding F351A Small Molecule For Treating Fibrotic Diseasesand Cb 2782 Pega Complement Inhibitor Aimed At Dry Age Related Macular Degenerationamd The Company Has Shifted Its Focus From Hemophilia Therapies To Complement Therapeutics And Protease Medicinesresponding To Unmet Needs In Amd And Inflammatory Diseasesfollowing Its Merger In 2023Gyre Therapeutics Continues To Develop Its Pipeline While Exploring Strategic Opportunities In Fibrotic Disease Research And Development
